Barclays Sticks to Its Hold Rating for Equinor ASA (0M2Z)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rainforth covers the Energy sector, focusing on stocks such as Repsol, ENI S.p.A., and Equinor ASA. According to TipRanks, Rainforth has an average return of 5.0% and a 55.59% success rate on recommended stocks.
Currently, the analyst consensus on Equinor ASA is a Hold with an average price target of NOK267.20, which is a 2.31% upside from current levels. In a report released on June 27, Morgan Stanley also maintained a Hold rating on the stock with a NOK248.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
36 minutes ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NextCure (NXTC – Research Report), Lexaria Bioscience (LEXX – Research Report) and Travere Therapeutics (TVTX – Research Report) with bullish sentiments. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. NextCure (NXTC) In a report issued on July 1, Emily Bodnar from H.C. Wainwright maintained a Buy rating on NextCure, with a price target of $3.00. The company's shares closed last Thursday at $0.44. According to Bodnar is ranked 0 out of 5 stars with an average return of -6.6% and a 29.4% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Acrivon Therapeutics, Inc., and TransCode Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NextCure with a $3.00 average price target. Lexaria Bioscience (LEXX) In a report issued on July 1, Yi Chen from H.C. Wainwright reiterated a Buy rating on Lexaria Bioscience, with a price target of $5.00. The company's shares closed last Thursday at $0.90. According to Chen 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.9% and a 37.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Orchestra BioMed Holdings, and Bausch + Lomb Corporation. The the analyst consensus on Lexaria Bioscience is currently a Hold rating. Travere Therapeutics (TVTX) Travere Therapeutics received a Buy rating and a $30.00 price target from H.C. Wainwright analyst Joseph Pantginis on July 1. The company's shares closed last Thursday at $15.01. According to Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.8% and a 30.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Adlai Nortye Ltd. Sponsored ADR, and Bioline RX Ltd Sponsored ADR. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $34.00 average price target, representing a 128.8% upside. In a report issued on June 16, Evercore ISI also maintained a Buy rating on the stock with a $45.00 price target.
Business Insider
2 hours ago
- Business Insider
Bayerische Motoren Werke Aktiengesellschaft (BAMXF) Receives a Hold from HSBC
In a report released yesterday, Mike Tyndall from HSBC maintained a Hold rating on Bayerische Motoren Werke Aktiengesellschaft, with a price target of €77.00. The company's shares closed last Thursday at $91.88. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Tyndall covers the Consumer Cyclical sector, focusing on stocks such as Tesla, Mercedes-Benz Group, and Stellantis. According to TipRanks, Tyndall has an average return of -5.5% and a 38.98% success rate on recommended stocks. Currently, the analyst consensus on Bayerische Motoren Werke Aktiengesellschaft is a Moderate Buy with an average price target of $97.68, implying a 6.32% upside from current levels. In a report released on July 1, RBC Capital also maintained a Hold rating on the stock with a €79.00 price target. The company has a one-year high of $103.61 and a one-year low of $68.23. Currently, Bayerische Motoren Werke Aktiengesellschaft has an average volume of 2,291.
Business Insider
2 hours ago
- Business Insider
Redburn Atlantic Sticks to Its Buy Rating for Persimmon (PSN)
Redburn Atlantic analyst Will Jones maintained a Buy rating on Persimmon yesterday and set a price target of £15.75. The company's shares closed yesterday at p1,210.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Jones is a 3-star analyst with an average return of 36.2% and a 100.00% success rate. Jones covers the Consumer Cyclical sector, focusing on stocks such as Bellway, The Berkeley Group Holdings, and Vistry Group. Currently, the analyst consensus on Persimmon is a Moderate Buy with an average price target of p1,555.00, representing a 28.51% upside. In a report released on June 24, Morgan Stanley also maintained a Buy rating on the stock with a £15.60 price target.
